Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Rimegepant

An oral antagonist of the receptor for CGRP, the peptide involved in triggering migraine, of the 'gepant' class: approved in the United States in 2020 for the acute treatment of migraine attacks. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.

Did you know?In 2021 it became the first medicine approved both to treat migraine attacks and to prevent them; it is taken as an orally disintegrating tablet that dissolves in the mouth.

RimegepantGo to the active ingredient →
RimegepantActive ingredientRimegepantCat. No. P-R062-001CAS 1289023-67-1

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.